CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a late-stage biopharmaceutical company developing subcutaneous and oral PCSK9 inhibitor therapies for patients at very high and high-risk of ...
Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – that can be used to reduce cholesterol levels. The injectable product has ...
CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor for patients at very ...
Exclusive: Ed Davey to make call ahead of 10th anniversary of Brexit vote, in strengthening of party’s position on EU ...
CINCINNATI, May 11, 2026--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company, today announced the U.S. commercial launch of LEROCHOL® (lerodalcibep-liga) ...
The FDA has greenlighted LIB Therapeutics' third-generation PCSK9 inhibitor, Lerochol, which lowers LDL-C cholesterol and has a convenience edge over its PCSK9 ...
With voter loyalty a distant memory, the Lib Dems’ cost of living policies and criticism of Trump could gain them ground It has been an election buildup dominated by the rise of Reform UK and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results